Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-Blind, Placebo Controlled, Flexible Dose, Parallel Group Study of Extended-Release Lorazepam (EDG004) for the Treatment of Generalized Anxiety Disorder (GAD)

NCT02305797 is registered in ClinicalTrials.gov with Edgemont Pharmaceuticals, LLC as lead sponsor.

NCT NCT02305797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02305797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-Blind, Placebo Controlled, Flexible Dose, Parallel Group Study of Extended-Release Lorazepam (EDG004) for the Treatment of Generalized Anxiety Disorder (GAD)
Lead sponsor
Edgemont Pharmaceuticals, LLC
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2015
Completion date
May 31, 2016
Enrollment
495 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

generalized anxiety disorder (gad)